Nuo Therapeutics Inc (AURX)
0.75
0.00 (0.00%)
USD |
OTCM |
May 17, 16:00
Nuo Therapeutics Gross Profit Margin (Quarterly): 79.00% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 79.00% |
| September 30, 2023 | 76.83% |
| June 30, 2023 | 82.66% |
| March 31, 2023 | 82.95% |
| December 31, 2022 | 82.81% |
| September 30, 2022 | 83.02% |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| December 31, 2019 | -258.7% |
| September 30, 2019 | 40.04% |
| June 30, 2019 | 23.85% |
| March 31, 2019 | 26.84% |
| December 31, 2018 | 96.19% |
| September 30, 2018 | 82.77% |
| June 30, 2018 | 72.36% |
| March 31, 2018 | 69.36% |
| December 31, 2017 | -41.56% |
| September 30, 2017 | -62.76% |
| June 30, 2017 | -47.07% |
| Date | Value |
|---|---|
| March 31, 2017 | -56.35% |
| September 30, 2016 | -57.04% |
| March 31, 2016 | 43.96% |
| December 31, 2015 | 27.93% |
| September 30, 2015 | 26.24% |
| June 30, 2015 | 17.73% |
| March 31, 2015 | 41.59% |
| December 31, 2014 | -9.91% |
| September 30, 2014 | 21.14% |
| June 30, 2014 | 18.43% |
| March 31, 2014 | 21.28% |
| December 31, 2013 | 14.20% |
| September 30, 2013 | 15.34% |
| June 30, 2013 | 43.95% |
| March 31, 2013 | 45.09% |
| December 31, 2012 | 48.25% |
| September 30, 2012 | 43.28% |
| June 30, 2012 | 73.41% |
| March 31, 2012 | 71.88% |
| December 31, 2011 | 75.44% |
| September 30, 2011 | 53.22% |
| June 30, 2011 | 54.15% |
| March 31, 2011 | 52.74% |
| December 31, 2010 | 55.91% |
| September 30, 2010 | 58.81% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-258.7%
Minimum
Dec 2019
83.02%
Maximum
Sep 2022
32.50%
Average
79.00%
Median
Dec 2023
Gross Profit Margin (Quarterly) Benchmarks
| AIM ImmunoTech Inc | 81.54% |
| Perspective Therapeutics Inc | -- |
| Protalix BioTherapeutics Inc | 30.58% |
| Electromed Inc | 74.85% |
| Armata Pharmaceuticals Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -275.0% |
| Return on Assets | -156.5% |
| Return on Invested Capital | -275.0% |
| Profit Margin (Quarterly) | -331.5% |
| Operating Margin (Quarterly) | -331.0% |
| Return on Net Operating Assets | -413.5% |